Tuesday: FDA panel reviews Merck's Ragwiteck

Share this article:

Merck's prescription allergy medication Ragwitek is going before the FDA Allergenic Products Advisory Committee tomorrow, and the panel's discussion documents indicate the under-the-tongue medication is not associated with serious safety concerns, reports Reuters.

An FDA approval would provide an alternative to injections doctors typically give for pollen and ragweed allergies.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.